US Pharma MarketingA look at two recent CRLs demonstrate the tension and discrepancies between how companies and the agency communicate drug rejections.
What’s in the FDA’s latest batch of rejection letters
A look at two recent CRLs demonstrate the tension and discrepancies between how companies and the agency communicate drug rejections.
Source: PharmaVoice